

# Biosynthesis of Bisabolene by Callus Cultures of *Andrographis paniculata*

By KARL H. OVERTON\* and DOUGLAS J. PICKEN

(Plant Tissue Culture Unit, Department of Chemistry, The University of Glasgow, Glasgow G12 8QQ)

**Summary** Experiments with intact callus cultures of *Andrographis paniculata* and a derived cell-free system indicated that (a) the biosynthesised  $\gamma$ -bisabolene has the *Z*-configuration (3); (b) the biosynthetic intermediate is 2-*cis*,6-*trans*-(1)- and not 2-*cis*,6-*cis*-(2)-farnesol pyrophosphate; (c) in paniculide B (5) the ring carbon derived from C-2 of mevalonate is *anti* to the side chain.

ON a speculative level  $\gamma$ -bisabolene or cations derived from it are important early intermediates in the biosynthesis of a variety of natural sesquiterpenoids.<sup>1,2</sup> Suggestions for the biosynthesis of  $\gamma$ -bisabolene itself were made by Ruzicka in 1962<sup>3</sup> but, so far as we are aware, have not been subjected to experimental scrutiny. Indeed there is, to our knowledge, no convincing recorded evidence that identifies natural  $\gamma$ -bisabolene as either the *Z*- or *E*-isomer.

The suggested pathways to  $\gamma$ -bisabolene [(3) or (4)] pose two questions: (a) is the ring carbon atom derived from C-2 of mevalonate *anti* (3) or *syn* (4) to the side chain and (b) is 2-*cis*,6-*trans*-(1)- or 2-*cis*,6-*cis*-(2)-farnesol pyrophosphate the intermediate? In addition, since an enzyme-mediated double bond isomerisation of either (3) or (4) cannot be excluded *a priori*, independent evidence is desirable to identify natural  $\gamma$ -bisabolene as either the *Z*- or *E*-isomer.

We have attempted to distinguish between these alternatives by using callus cultures of *A. paniculata* and cell-free systems derived from them.<sup>4,5</sup> The callus cultures grown in suspension in presence of oxygen and light accumulate the sesquiterpene lactones paniculides A, B, and C, previously described.<sup>6</sup> The derived cell-free system under anaerobic conditions accumulates  $\gamma$ -bisabolene, as well as *trans,trans*- and *cis,trans*-farnesols.<sup>5</sup>

TABLE


<sup>13</sup>C Chemical shifts of paniculide B and coupling constants [ $^1J(^{13}\text{C}-^{13}\text{C})/\text{Hz}$ ] of [1,2-<sup>13</sup>C<sub>2</sub>]acetate-enriched paniculide B.

Carbon	1	2	3	4	5	6	7	8
$\delta/\text{p.p.m.}^a$	25.3	131.3	123.5	27.1	22.8	126.4	161.0	75.2
$^1J(^{13}\text{C}-^{13}\text{C})$	—	42	43	44	—	62	35	35
Carbon	9	10	11	12	13	14	15	
$\delta/\text{p.p.m.}$	32.7	60.1	61.8	67.2	17.4	173.3	63.6	
$^1J(^{13}\text{C}-^{13}\text{C})$	—	49	46	46	42	63	49	

<sup>a</sup> Relative to internal Me<sub>4</sub>Si.

An answer to question (a) above came from examination of the <sup>13</sup>C n.m.r. spectrum of paniculide B [(5) or (6)], biosynthesised from [1,2-<sup>13</sup>C<sub>2</sub>]acetate by callus tissues. Carbon 2 of mevalonic acid will appear in paniculide B either at C-9 (5) or at C-11 (6) (and also at C-1 and C-5). Unlike the corresponding carbon atoms in the  $\gamma$ -bisabolene precursor, C-9 and C-11 of paniculide B are readily distinguishable in its <sup>13</sup>C n.m.r. spectrum and indeed the complete spectrum was unambiguously assignable (see Table) using samples enriched in turn by [1-<sup>13</sup>C]-, [2-<sup>13</sup>C]-, and [1,2-<sup>13</sup>C<sub>2</sub>]-acetates. When [1,2-<sup>13</sup>C<sub>2</sub>]acetate served as precursor [151 mg, 91.7 atom %, administered to callus tissue (dry weight 2.55 g) grown in suspension for 20 days following transfer from

solid medium<sup>4,5</sup>] and paniculide B (117 mg, t.l.c.-pure) was harvested after 10 days, C-9, ( $\delta$  32.7 p.p.m. from Me<sub>4</sub>Si; Varian XL-100 at 25.2 MHz) appeared essentially as a singlet and therefore derives from C-2 of mevalonate,<sup>7</sup> while C-11 ( $\delta$  61.8 p.p.m.) appeared as a triplet [singlet + doublet ( $J_{11,12}$  45.9 Hz)] (see Table). It follows that paniculide B is represented by (5) and not (6) and its  $\gamma$ -bisabolene precursor probably by (3) and not (4). This



conclusion is supported by incorporation of radioactivity from labelled mevalonate into *Z*- $\gamma$ -bisabolene (3), but not into the *E*-isomer (4). Thus co-injection (Pye 104 gas chromatograph with Panax Nucleonics Radiogas Detection System; 1% SE30 at 110 °C) of  $\gamma$ -bisabolene biosynthesised

by the cell-free system<sup>5</sup> from (3*R*)-[2-<sup>14</sup>C]mevalonate, and a mixture of synthetic *Z*- and *E*- $\gamma$ -bisabolenes, located radio-activity in only the *Z*-isomer.<sup>8</sup>

That *cis,trans*- and not *cis,cis*-farnesol pyrophosphate is the biosynthetic intermediate to  $\gamma$ -bisabolene was established as follows. (3*R*)-[2-<sup>14</sup>C,5-<sup>3</sup>H<sub>2</sub>]mevalonate was incorporated into  $\gamma$ -bisabolene (1.2% incorporation, estimated as crystalline trihydrochloride of constant radio-activity) with loss of one-sixth of the tritium label (%<sup>3</sup>H retention 85.4, 80.2; one-sixth <sup>3</sup>H loss requires 83.3). This supports the intermediacy of *cis,trans*-farnesol pyrophosphate (loss of one-sixth <sup>3</sup>H in *trans,trans*- to *cis,trans*-interconversion<sup>9</sup>),

but not of *cis,cis*-farnesol pyrophosphate which should lose an additional one-sixth <sup>3</sup>H label at the C<sub>10</sub> stage during geraniol to nerol interconversion.<sup>5,9</sup> More directly, [4,8,12-<sup>14</sup>C<sub>3</sub>]-*cis,trans*-farnesol<sup>5</sup> was incorporated (1.2%) into  $\gamma$ -bisabolene, but [2-<sup>14</sup>C]-*cis,cis*-farnesol<sup>10</sup> was not (0.02%).

We thank Miss I. Freer for the maintenance and culturing of *Andrographis* tissue, the S.R.C. for a studentship (to D.J.P.), Dr. I. H. Sadler, Edinburgh University, for <sup>13</sup>C n.m.r. spectra, and Dr. D. J. Faulkner, La Jolla, California, for synthetic *E*- and *Z*-bisabolene.

(Received, 19th November, 1975; Com. 1295.)

<sup>1</sup> W. Parker, J. S. Roberts, and R. Ramage, *Quart. Rev.*, 1967, **21**, 331.

<sup>2</sup> G. Rücker, *Angew. Chem. Internat. Edn.*, 1973, **12**, 793.

<sup>3</sup> L. Ruzicka, *Pure Appl. Chem.*, 1963, **6**, 493.

<sup>4</sup> D. N. Butcher and J. D. Connolly, *J. Exper. Botany*, 1971, **22**, 314.

<sup>5</sup> F. M. Roberts and K. H. Overton, *Biochem. J.*, 1974, **144**, 585.

<sup>6</sup> A. J. Allison, D. N. Butcher, J. D. Connolly, and K. H. Overton, *Chem. Comm.*, 1968, 1493.

<sup>7</sup> M. Tanabe and K. T. Suzuki, *J.C.S. Chem. Comm.*, 1974, 445.

<sup>8</sup> The *E*- and *Z*-isomers have recently been identified by X-ray structure analysis of a synthetic intermediate: L. E. Wolinsky, D. J. Faulkner, J. Finer, and J. Clardy, *J. Org. Chem.*, in the press. We are indebted to Dr. Faulkner for pre-publication information.

<sup>9</sup> E. Jedlicki, G. Jacob, F. Faini, and O. Cori, *Arch. Biochem. Biophys.*, 1972, **152**, 590.

<sup>10</sup> Prepared from methyl bromo[2-<sup>14</sup>C]acetate, triethyl phosphite, and neryl acetone; see 'Methods in Enzymology,' ed. R. B. Clayton, Vol. XV, Academic Press, New York, 1969; pp. 378, 379.